SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing significant selling pressure and heightened volatility, as traders actively debate whether the stock is a long-term value opportunity or stuck in a "trough of chaos." Community sentiment remains deeply divided, with many expressing frustration over the stock's persistent decoupling from broader market rallies while focusing heavily on the implications of heavy AI infrastructure spending and ongoing antitrust scrutiny.

The Shrimp Army

The Shrimp Army is gaining traction as part of a broader trend of sea-themed memecoins, sparking intense debate among community members over its potential for rapid growth versus risks of being a speculative pump-and-dump. Traders are actively monitoring the token's ability to maintain upward momentum and consolidate at higher valuation levels.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is facing intense downward pressure driven by regulatory headwinds, specifically the potential state and federal restrictions on prediction markets, alongside ongoing legal challenges regarding trademark usage and addiction concerns. The community is actively debating the stock's long-term viability, with many retail traders expressing frustration over persistent insider selling and a lack of clear support levels.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech100 is drawing significant investor attention as the primary proxy for the highly anticipated SpaceX IPO, with community members actively debating the fund's premium-to-NAV compared to alternative holdings. The surge in volume and social sentiment reflects a strategic rotation by retail traders seeking concentrated exposure to private tech unicorns like SpaceX, Anthropic, and OpenAI ahead of potential liquidity events.

PRIME is the native token of the Echelon Prime Foundation, a Web3 ecosystem advancing the next generation of gaming. Echelon creates and distributes tools to encourage innovation in, and promote the growth of, novel gaming models and economies. The first game to adopt and utilize PRIME is Parallel, a sci-fi trading card game.

Echelon Prime

Echelon Prime is trending as community members point to signs of quiet accumulation and a potential bullish reversal for the gaming token. Traders are actively debating the token's role in the future of on-chain gaming economies, with sentiment divided between optimism for a recovery and frustration over recent volatility.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is facing intense volatility and selling pressure following a aggressive short report from Culper Research that alleges the company is engaged in channel stuffing and misleading financial reporting. While the company has officially pushed back, dismissing the claims as inaccurate and speculative, the community remains divided and highly anxious, with long-term supporters debating whether to hold through the uncertainty or exit as they wait for more substantial management responses and potential insider buying.

Fundrise Growth Tech Fund LLC operates as a non-diversified, closed-end management investment company. It invests in growing tech companies to help them expand and generate profits. The company was founded on June 7, 2021 and is headquartered in Washington, DC.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is trending as investors debate whether the fund's parabolic run is driven by genuine exposure to high-growth AI and aerospace giants like SpaceX and Anthropic or if it has entered bubble territory due to its massive premium to Net Asset Value. The community remains sharply divided, with many actively hunting for alternative "catch-up" plays like DXYZ and RVI while others warn of a potential liquidity trap once lock-up periods expire.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is generating significant buzz ahead of an upcoming AAD conference late-breaking session, where the community expects positive 40-week efficacy data to confirm SLK as a best-in-class treatment for Hidradenitis Suppurativa. Investors are closely monitoring analyst upgrades, potential M&A activity, and institutional accumulation, hoping the data will finally put persistent buyout rumors and clinical skepticism to rest.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is currently experiencing high volatility following a quarterly earnings report that featured a revenue and EPS beat alongside raised full-year guidance, though initial market reaction was cautious. The community is actively debating the stock's high valuation relative to its growth phase, with many bullish traders highlighting its critical role in AI infrastructure and data center CPU expansion as reasons to buy the dip, while others express concerns over potential overvaluation and broad tech sector cooling.

Intercontinental Exchange, Inc. engages in the provision of market infrastructure, data services and technology solutions. It operates through the following segments: Exchanges, Fixed Income and Data Services, and Mortgage Technology. The Exchanges segment operates marketplace technology for the listing, trading, and clearing of derivatives contracts and financial securities, as well as data and connectivity services. The Fixed Income and Data Services segment provides fixed income pricing, reference data, indices, analytics, and execution services as well as global credit default swap, or CDS, clearing, and multi-asset class data delivery technology. The Mortgage Technology segment provides a technology platform that offers digital workflow tools to address inefficiencies and mitigate risks that exist in the US residential mortgage market lifecycle from application through closing, servicing, and the secondary market. The company was founded by Jeffrey C. Sprecher in 2000 and is headquartered in Atlanta, GA.

Intercontinental Exchange Inc

Intercontinental Exchange (ICE) is currently the focus of market attention due to its strategic push into tokenized securities and its high-profile investment in Polymarket, which signals a broader Wall Street pivot toward on-chain infrastructure. Traders are closely monitoring the stock's potential for growth as the NYSE owner leans into digital asset innovation and institutional crypto adoption, with community sentiment shifting between excitement over these technological partnerships and caution regarding broader market volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing

In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $58.94, denoting a +2.7% move from the preceding trading day.

Will the Recent Label Expansion of BMY's Opdivo Boost Its IO Franchise?

Bristol Myers Squibb's Opdivo expansions highlight pharma companies' push to grow oncology franchises amid rising competition and pipeline innovation.

Procyon Advisors LLC Sells 20,349 Shares of Bristol Myers Squibb Company $BMY

Procyon Advisors LLC trimmed its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 56.8% during the fourth quarter, according to the company in its most recent 13F filing with the...

E. Ohman J or Asset Management AB Buys 46,000 Shares of Bristol Myers Squibb Company $BMY

E. Ohman J or Asset Management AB boosted its stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 183.2% during the fourth quarter, according to its most recent Form 13F filing with the...

<ul class="summary-bullets"><li>Founder Patrick Soon-Shiong said Abraxane from Bristol Myers Squibb could help boost immune responses when combined with the company’s cancer immunotherapy Anktiva.</li><li>Founder Patrick Soon-Shiong said Abraxane may help “expose” tumors through immune-activating signals and support macrophage activity.</li><li>Anktiva was recently added to Macau’s approved drug list and included by the National Comprehensive Cancer Network for certain bladder cancer patients.</li></ul>Shares of ImmunityBio, Inc. (IBRX)&nbsp;rose over 1% in premarket trading on Tuesday after a newly posted Phase 1 study showed its cancer therapy Anktiva is being tested alongside Bristol Myers Squibb’s Abraxane and other drugs in patients with pancreatic cancer ahead of surgery.<a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> jumped nearly 11% on Monday, marking its best session in a month.<h2 class="st-heading-2">Phase 1 Trial Tests Anktiva In Pancreatic Cancer</h2>According to a new regulatory update on Monday, the open-label Phase 1 study is evaluating Anktiva in combination with the investigational agents Sotevtamab and Zabadinostat, plus the chemotherapy drugs Gemcitabine and Abraxane, in participants with borderline resectable or locally advanced pancreatic ductal adenocarcinoma.The treatment is being given before surgery, followed by tumor removal and additional immunotherapy afterward, as researchers evaluate the safety and early signals of effectiveness of the combination approach.Participants enrolled in the study will undergo endoscopic ultrasound-guided biopsies of the primary tumor within seven days before treatment begins. Samples will be used for diagnostic evaluation and stored in an approved tissue bank.<h2 class="st-heading-2">Bristol Myers’ Abraxane May Support Anktiva</h2>Soon-Shiong&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DrPatrick/status/2036321510348947567">said on X</a> that Abraxane differs from older chemotherapy agents such as Taxol because it is delivered using albumin, a naturally occurring protein that helps transport the drug across blood vessel walls into the tumor microenvironment.He said the drug enters tumors through a natural transport pathway called GP60 and helps activate macrophages to attack cancer cells while also “exposing” tumors through DAMP signaling, making them easier for natural killer (NK) cells and T cells to recognize and destroy.“So it’s not that we ignore the use of chemo, it’s how we use it to activate the immune system while protecting and activating the lymphocytes with Anktiva,” Soon-Shiong said. Abraxane was originally developed by Abraxis BioScience, which Soon-Shiong founded, and is now marketed by Bristol Myers Squibb for breast, lung and pancreatic cancers.<h2 class="st-heading-2">Anktiva Platform Therapy Strategy Gains Support</h2>The development adds to ImmunityBio’s broader effort to position Anktiva as a platform immunotherapy that works alongside vaccines, checkpoint inhibitors and chemotherapy backbones across multiple cancer types rather than as a standalone treatment.Last week, Soon-Shiong pointed to&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-premarket-early-anktiva-immune-data-macau-nod-bull-case/cZ3Xl3sRILc">early immune data</a> from the first 20 participants in an Anktiva study showing increases in absolute lymphocyte counts when the therapy was used with the company’s adenovirus-based cancer vaccine. The trial has enrolled 138 patients randomized to the combination or placebo.He said baseline lymphocyte levels typically decline with age but appeared to increase with Anktiva in the early analysis, supporting the therapy’s immune-stimulating role.<h2 class="st-heading-2">Anktiva Gains Macau Listing, NCCN Backing</h2>Momentum around Anktiva has also been driven by recent regulatory developments, including its addition to&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-snap-losing-streak-anktiva-macau-drug-list/cZ3XLBrRIhU">Macau’s approved</a> drug list for bladder cancer. Anktiva now stands alongside therapies from Bristol Myers Squibb, Eli Lilly, Vertex Pharmaceuticals, Gilead Sciences and Moderna in Macau.&nbsp;In the U.S., the National Comprehensive Cancer Network (NCCN) added Anktiva with BCG as an “other recommended” option for papillary bladder cancer that no longer responds to standard BCG treatment, expanding its positioning beyond carcinoma in situ under treatment guidelines.ImmunityBio has also resubmitted its application seeking to expand Anktiva’s label to papillary bladder cancer after previously receiving a refusal-to-file letter from regulators.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for IBRX has slipped to ‘bearish’ levels over the past week from the ‘extremely bullish’ zone amid ‘low’ message volumes over the last 24-hours.<figure class="image"><img src="https://news.stocktwits-cdn.com/ibrx_ss_png_68b9bc5725.webp" alt="ibrx ss.png" width="973" height="145"><figcaption>IBRX sentiment and message volume as of March 24 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/PureLand/message/648355601">said</a> IBRX shares showed signs of steady accumulation after closing near session highs and, citing recent regulatory and guideline momentum. They expect the stock to climb toward $20 by Friday.<stembedurl>https://stocktwits.com/PureLand/message/648355601</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Dirk1969/message/648354937">said</a> IBRX is “currently the best stock with the most potential.”<stembedurl>https://stocktwits.com/Dirk1969/message/648354937</stembedurl>IBRX stock has surged nearly 250% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the ImmunityBio logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

IBRX Stock Rises Premarket: Anktiva Moves Into Pre-Surgery Pancreatic Cancer Combo Trial With Bristol Myers Drug

The comments come amid the firm’s strategy to position Anktiva as a platform immunotherapy that works along with vaccines, checkpoint inhibitors and chemotherapy.

Equity

Diversified Trust Co. Has $6.82 Million Stock Holdings in Bristol Myers Squibb Company $BMY

Diversified Trust Co. grew its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 25.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 126,336 shares of the biopharmaceutical company's stock a...

FDA Approves BMY's Opdivo Label Expansion in Classical Hodgkin Lymphoma

Bristol Myers expands Opdivo's reach with new U.S. and EU approvals in Hodgkin lymphoma, strengthening its immunotherapy leadership and growth outlook.

Can Anktiva's Label Expansion Unlock the Next Growth Phase for IBRX?

ImmunityBio bets on Anktiva label expansion to drive growth, but intense Big Pharma competition and premium valuation raise questions about its next phase.

Wealth Enhancement Advisory Services LLC Purchases 318,898 Shares of Bristol Myers Squibb Company $BMY

Wealth Enhancement Advisory Services LLC raised its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 26.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,533,355 shares of the biopharmaceutica...

Bristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos (mavacamten) Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26)

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of new clinical trial and real-world data for Camzyos (mavacamten) at the American College of Cardiologys (ACC) Annual Scientific...

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

BMY
Bristol-Myers Squibb Co.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BMY News

BMYBristol-Myers Squibb Co.